Discovering genetic biomarkers for targeted cancer therapeutics with eXplainable Artificial Intelligence

Debaditya Chakraborty; Elizabeth Gutierrez-Chakraborty; Cristian Rodriguez-Aguayo; Hakan Başağaoğlu; Gabriel Lopez-Berestein; Paola Amero

doi:10.1002/cac2.12530

Cancer Communications ›› 2024, Vol. 44 ›› Issue (5) :584 -588. DOI: 10.1002/cac2.12530

LETTER TO THE JOURNAL

Discovering genetic biomarkers for targeted cancer therapeutics with eXplainable Artificial Intelligence

Author information +

History +

PDF

Cite this article

Download citation ▾

Debaditya Chakraborty, Elizabeth Gutierrez-Chakraborty, Cristian Rodriguez-Aguayo, Hakan Başağaoğlu, Gabriel Lopez-Berestein, Paola Amero. Discovering genetic biomarkers for targeted cancer therapeutics with eXplainable Artificial Intelligence. Cancer Communications, 2024, 44(5): 584-588 DOI:10.1002/cac2.12530

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17-48.

[2]	Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC,, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15(11):668-679.

[3]	Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, et al. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020;31(9):1240-1250.

[4]	Garsed DW, Pandey A, Fereday S, Kennedy CJ, Takahashi K, Alsop K, et al. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nature genetics. 2022;54(12):1853-1864.

[5]	Shmatko A, Ghaffari Laleh N, Gerstung M, Kather JN. Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. Nat Cancer. 2022;3(9):1026-1038.

[6]	Kundu S. AI in medicine must be explainable. Nature Medicine. 2021;27(8):1328.

[7]	Dibra D, Mitra A, Newman M, Xia X, Cutrera JJ, Gagea M, et al. Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo. Clin Cancer Res. 2016;22(15):3876-3883.

[8]	Aghayev T, Mazitova AM, Fang JR, Peshkova IO, Rausch M, Hung M, et al. IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma. Cancer discovery. 2022;12(8):1960-1983.